Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: Predictive factors of treatment response;Association cyclophosphamide-méthylprednisolone en traitement de fond des scléroses en plaques de type progressif: Facteurs prédictifs d'une réponse clinique

Revue Neurologique

Volumn 160, Issue 6-7, 2004, Pages 659-665

  Delmont, E ^a   Chanalet, S ^a   Bourg, V ^a   Soriani, M H ^a   Chatel, M ^a   Lebrun, C ^a,b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

Chemotherapy; Cyclophosphamide; Multiple sclerosis; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; MESNA; METHYLPREDNISOLONE; UROMITHEXAN;

ADULT; AGE; ARTICLE; DISABILITY; DISEASE COURSE; DRUG PULSE THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROGNOSIS; RELAPSE; TREATMENT OUTCOME;

EID: 3843106815     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(04)71015-2     Document Type: Article

References (36)

1. CARTER JL, HAFLER DA, DAWSON DM, et al. (1988). Immunosuppression with high dose intravenous cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology, 38: 9-14.
2. CHANALET S, LEBRUN C, RAFFAELLI CP, PADOVANI B. (2000). Long-term outcomes of radiologically placed arm ports: prospective study in a multiple sclerosis population. Mult Scler, (suppl 1): 6.
3. COHEN J, GOODMAN A, HEIDENREICH F. (2001). Results of IMPACT, a phase III trial of Interferon beta-1a in secondary progressive multiple sclerosis. Neurology, 56: A148.
4. DE RIDDER D, VAN POPPEL H, DEMONTY L, et al. (1998). Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol, 159: 1881-1884.
5. EUROPEAN STUDY GROUP ON INTERFERON β 1B IN SECONDARY PROGRESSIVE MS. (1998). Placebo controlled placebo multicentre randomized trial of Interferon β 1b in treatment of secondary progressive multiple sclerosis. Lancet, 352: 1491-1497.
6. GAUTHIER S, BHARANIDHARAN P, STAZZONE L, et al. (2003). Treatment of relapsing remitting interferon/glatiramer acetate unresponsive patients with pulse cyclophosphamide. Neurology, 60 suppl 1: A148.
7. GOODKIN DE, PLENCER S, PALMER SJ, et al. (1987). Cyclophosphamide in chronic progressive multiple sclerosis: maintenance versus non-maintenance therapy. Arch Neurol, 44: 823-827.
8. GOODKIN DE AND THE NORTH AMERICAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS. (2000). Interferon beta-1b in secondary progressive multiple sclerosis: clinical and MRI results of a 3 years randomized controlled trial. Neurology, 54: 2352.
9. HARTUNG HP, GONSETTE R, KONIG N et al. (2002). Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomised, multicenter trial. Lancet, 360:2018-2025.
10. HAUSER SL, DAWSON DM, LEHRICH JR, et al. (1983). Intensive immunosuppression in progressive multiple sclerosis: a randomised, three arms study of high dose intraveinous cyclophosphamide, plasma exchange and ACTH. N Engl J Med, 308: 173-180.
11. HOHOL MJ, MACKIN GA, DAUSON DM, et al. (1992). Pilot study of three years intermittent pulse cyclophosphamide/methylprednisolone therapy in multiple sclerosis. Ann Neurol, 32: 256-257.
12. HOHOL MJ, OLEK MJ, ORAV EJ et al. (1999). Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler, 5: 403-409.
13. HOMMERS OR, WEINER HL. (2002). Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis. Mult Scler, 8: 139-141.
14. INTERFERON β MULTIPLE SCLEROSIS STUDY GROUP. (1993). Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter randomized, double-blind, placebo-controlled-trial. Neurology, 43: 655-661.
15. JACOBS LD, COOKFAIR LD RUDICK RA, et al. (1996). Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. Ann Neurol, 39: 285-294.
16. JOHNSON KP, BROOKS BR, COHEN JA, et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: result of a phase II multicenter, double-blind, placebo controlled trial. Neurology, 45: 1268-1276.
17. KURTZKE JF. (1983). Rating neurological impairement in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33: 1444-1452.
18. LA MANTIA L, EOLI M, SALMAGGI A, et al. (1998). Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Ital J Neurol Sci, 19: 32-36.
19. LIKOSKY WH, FIREMAN B, ELMORE R. (1991). Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry, 54: 1054-1060.
20. LUBLIN FD, REINGOLD SC. (1996). Defining the clinical course of multiple sclerosis: result of an international survey. Neurology, 46: 907-911.
21. LUCCHINETTI C, BRUCK W, PARISI J, et al (2000). Heterogeinity of multiple sclerosis lesions: implication for the pathogenesis of demyelisation. Ann Neurol, 47: 707-717.
22. MAC DONALD WI, COMPSTON A, EDAN G et al. (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol, 50: 121-127.
23. MONTALBAN X, BRIEVA L, TINTORE M. (2002). Single center, DBPC, randomized trial of interferon beta 1-b in primary progressive multiple sclerosis and transitional progressive multiple sclerosis: an exploratory phase II study. Mult Scler, 8 (suppl 1): S19.
24. PATTI F, REGGIO E, FIORILLA T, et al. (2003). Rapidly transitional multiple sclerosis patients treated with combination of cyclophosphamide and interferon beta; follow-up 36 months after discontinuation of therapy. Neurology, 60 (suppl 1): A148-A149.
25. POSER CM, PATY DW, SCHEINBERG L, et al. (1983). New diagnostic criteria for multiple sclerosis: guidelines for research proposal. Ann Neurol, 13: 227-231.
26. PRISMS STUDY GROUP. (1998). Randomized double-blind placebo-controlled study of interferon beta 1-a in relapsing remitting multiple sclerosis. Lancet, 352: 1498-1504.
27. SMITH DR, WEINSTOCK-GUTTMAN B, COHEN JA, et al. (2003). Blinded, randomized trial of pulse cyclophosphamide in IFN Beta resistant active MS. Neurology, 60 (suppl 1): A84-A85.
28. SPECTRIMS. (2001). Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon β 1-a in Multiple Sclerosis. Neurology, 56: 1496-1504.
29. THE CANADIAN COOPERATIVE MULTIPLE SCLEROSIS STUDY GROUP. (1999). The Canadian cooperative trial of Cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet, 337: 441-446.
30. THOMPSON AJ, MONTALBAN X, BARKHOF F, et al. (2000). Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol, 47: 831-835.
31. VLAOVIC P, JEWETT MA. (1999). Cyclophosphamide-induced bladder cancer. Can J Urol, 6: 745-748.
32. WAKSMAN BH. (1981). Current trends in multiple sclerosis research. Immunol Today, 2: 87-93.
33. WEINER HL, MACKIN GA, ORAV EJ, et al. (1993). Intermittent Cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment group. Neurology, 43: 910-918.
34. WEINER HL, COHEN JA. (2002). Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler, 8: 142-154.
35. ZEPHIR H, DE SÉZE J, SÉNÉCHAL O, et al. (2002). Traitement des formes progressives de sclérose en plaques par le cyclophosphamide. Rev Neurol (Paris), 158: 65-69.
36. ZEPHIR H, DE SEZE J, DUHAMEL A, et al. (2003). Traitement des formes progressives de la sclérose en plaques par le cyclophosphamide. Une étude de cohorte portant sur 490 patients. Rev Neurol (Paris), 159 (Suppl): S79-S80.